Evidence map›Paper›PMID 40826136›Full record

ArticleActa neuropathologica communications2025

High-grade glioma with pleomorphic and pseudopapillary features: a single-institution series of three cases.

Eric A Goethe, Rasha Alfattal, Subhiksha Srinivasan, Pushan Dasgupta, Vinay Puduvalli, Shiao-Pei Weathers, Leomar Y Ballester, Jeffrey S Weinberg, Sujit Prabhu, Sherise D Ferguson and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta neuropathologica communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Neuro-oncology advances
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Eric A GoetheDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Rasha AlfattalDivision of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Subhiksha SrinivasanDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Pushan DasguptaDepartment of Neuro-oncology, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Vinay PuduvalliDepartment of Neuro-oncology, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Shiao-Pei WeathersDepartment of Neuro-oncology, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Leomar Y BallesterDivision of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Jeffrey S WeinbergDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Sujit PrabhuDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Sherise D FergusonDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Maria A GubbiottiDivision of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. magubbiotti@mdanderson.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionModern molecular diagnostic techniques such as DNA methylation profiling are leading to the reclassification of several central nervous system malignancies and discovery of novel diagnostic entities, such as high-grade glioma with pleomorphic and pseudopapillary features (HPAP).

methodsWe performed a retrospective chart review of all patients with HPAP confirmed with methylation profiling at a single institution between 2023 and 2025. Demographic, radiographic, surgical, and outcome data were collected.

resultsThree patients were identified: two females and one male with a mean age of 49.7 years (range 25-62). No patients had a prior cancer history. One patient had an incidentally discovered tumor, while the other two patients underwent imaging for symptoms of headache, vision changes and extremity weakness. Mean tumor size was 4.0 cm (range 2.8-6) with a wide variation in imaging characteristics. All patients underwent surgical resection and radiographic gross total resection was achieved in all cases. All patients underwent radiation therapy without concurrent chemotherapy. After a median 20 months follow up (range 4.5 to 108.9), two patients experienced tumor progression at 2.7 months and 86.5 months respectively. All patients were alive at last follow up.

conclusionHPAP is a novel clinical entity demonstrating variable molecular signatures sharing a common DNA methylation profile which demonstrates a relatively favorable clinical course when compared with other high grade gliomas. Further study is needed to determine the optimal treatment and factors that influence survival.

Indexed as

Brain NeoplasmsGliomaAdultDNA MethylationFemaleHumansMaleMiddle AgedNeoplasm GradingRetrospective Studies

Identifiers

PMID40826136
PMCPMC12363008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.